Active	Status	Sponsor type	Region	Phase	Filter
4 Active 7 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wagenlehner, Florian
ARASAFE, NCT05676203: A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients	Recruiting	3	250	Europe	Standard ADT (androgen deprivation therapy), Standard Darolutamide, Docetaxel	Jena University Hospital, Bayer	Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)	07/25	01/27
GPIU, NCT03665467: The Global Prevalence of Infections in Urology Study	Recruiting	N/A	2000	Europe		European Association of Urology Research Foundation	Hospital Infection, Urinary Tract Infections	01/21	12/21
Nowicki, Michal
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy	Active, not recruiting	3	404	Europe, Canada, Japan, US, RoW	Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo	Chinook Therapeutics, Inc.	IgA Nephropathy, Immunoglobulin A Nephropathy	12/26	12/26
NCT02355782: OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy	Available	N/A		Europe	OMS721	Michal Nowicki	Thrombotic Microangiopathy